Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMMNC therapy for incurable neurological disorders
NCT02245776Phase 1Withdrawn
- Sponsor
- NeuroGen Brain & Spine Institute
- Start
- Dec 2008
- Primary completion
- Jun 2018
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous bone marrow-derived mononuclear cell in neurological disorder, sponsored by NeuroGen Brain & Spine Institute. Primary endpoint: Change in clinical symptoms of neurological disorders at 1 year. Planned start Dec 2008; status: withdrawn.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
neurological disorder
Beyond the preview
Go deeper on NCT02245776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02245776.